MCS System NGDS-1 Program Announced as a Finalist in the Medical/Dental Category for the 2018 Edison Awards
Frederick, MD, February 26, 2018 --(PR.com)-- The Joint Project Management Office for Medical Countermeasure Systems (JPM-MCS) Next Generation Diagnostic System Increment 1 (NGDS Inc 1) program has been named a finalist in the Medical/Dental category for the 2018 Edison Awards.
Established in 1987 and often described as “the Oscars of Innovation,” the Edison Awards, named after Thomas Alva Edison, recognizes and honors the world’s best in innovators and innovations. The Edison Awards will announce gold, silver and bronze award winners at the 31st Annual Edison Awards, to be held Wednesday, April 11, 2018 in New York City.
Developed under the MCS Diagnostics Joint Product Management Office (MCS-DX), the NGDS Inc 1 FilmArray® system provides enhanced diagnostic and environmental identification capabilities. The system can test for the presence of biological warfare diseases in clinical samples using the Food and Drug Administration (FDA)-cleared Warrior Panel, as well as biological warfare agents in environmental samples on the Sentinel Panel, each in under 1 hour. The NGDS Inc 1 system can also utilize BioFire Defense LLC’s extensive commercial pipeline of over 105 different tests, further enhancing routine military medical care and expediting clinical decision making.The NGDS Inc 1 will be deployed across the military services, playing a critical role in the layered defense strategy to combat weapons of mass destruction.
All nominations were reviewed by the Edison Awards Steering Committee - which included representatives from large corporations such as Google, Apple, Dow Chemical, and Phillips Lighting - and the final ballot was sent to an independent judging panel. The judging panel was comprised of more than 3,000 professionals from the fields of product development, design, engineering, science, marketing and education, including professional organizations representing a wide variety of industries and disciplines.
About Medical Countermeasure Systems Diagnostics Joint Product Lead (MCS-DX)
MCS-DX develops, acquires, integrates, and fields identification technologies and FDA-cleared diagnostic systems for the U.S. military to aid in the diagnosis, prevention, and treatment of the effects of exposure to chemical, biological, and radiological warfare threats. It is a program within the U.S. Department of Defense’s Joint Project Manager Medical Countermeasure Systems (JPM-MCS), which facilitates the advanced development and acquisition of medical countermeasures and systems to enhance the biodefense response. JPM-MCS is a component of the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD).
About The Edison Awards
The Edison Awards is a program conducted by Edison Universe, a non-profit 501 (c)(3) organization dedicated to fostering future innovators. For more information about the Edison Awards, please visit www.edisonawards.com.
Established in 1987 and often described as “the Oscars of Innovation,” the Edison Awards, named after Thomas Alva Edison, recognizes and honors the world’s best in innovators and innovations. The Edison Awards will announce gold, silver and bronze award winners at the 31st Annual Edison Awards, to be held Wednesday, April 11, 2018 in New York City.
Developed under the MCS Diagnostics Joint Product Management Office (MCS-DX), the NGDS Inc 1 FilmArray® system provides enhanced diagnostic and environmental identification capabilities. The system can test for the presence of biological warfare diseases in clinical samples using the Food and Drug Administration (FDA)-cleared Warrior Panel, as well as biological warfare agents in environmental samples on the Sentinel Panel, each in under 1 hour. The NGDS Inc 1 system can also utilize BioFire Defense LLC’s extensive commercial pipeline of over 105 different tests, further enhancing routine military medical care and expediting clinical decision making.The NGDS Inc 1 will be deployed across the military services, playing a critical role in the layered defense strategy to combat weapons of mass destruction.
All nominations were reviewed by the Edison Awards Steering Committee - which included representatives from large corporations such as Google, Apple, Dow Chemical, and Phillips Lighting - and the final ballot was sent to an independent judging panel. The judging panel was comprised of more than 3,000 professionals from the fields of product development, design, engineering, science, marketing and education, including professional organizations representing a wide variety of industries and disciplines.
About Medical Countermeasure Systems Diagnostics Joint Product Lead (MCS-DX)
MCS-DX develops, acquires, integrates, and fields identification technologies and FDA-cleared diagnostic systems for the U.S. military to aid in the diagnosis, prevention, and treatment of the effects of exposure to chemical, biological, and radiological warfare threats. It is a program within the U.S. Department of Defense’s Joint Project Manager Medical Countermeasure Systems (JPM-MCS), which facilitates the advanced development and acquisition of medical countermeasures and systems to enhance the biodefense response. JPM-MCS is a component of the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD).
About The Edison Awards
The Edison Awards is a program conducted by Edison Universe, a non-profit 501 (c)(3) organization dedicated to fostering future innovators. For more information about the Edison Awards, please visit www.edisonawards.com.
Contact
JPM-MCS
Hannah Feldman
301-619-7400
https://www.jpeocbd.osd.mil/
Hannah Feldman
301-619-7400
https://www.jpeocbd.osd.mil/
Contact
Categories